Matches in SemOpenAlex for { <https://semopenalex.org/work/W137366449> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W137366449 abstract "Following the completion of Phase I trials, an investigational drug can move into Phase II trials, also known as therapeutic exploratory trials. As described in ICH Guidance E8: General Considerations for Clinical Trials, Phase II trials explore the use of a drug for its intended therapeutic indication by employing around 100-300 participants with the medical condition of concern. For example, an investigational antihypertensive drug would be given to participants with high blood pressure. Phase II trials, which are generally relatively short in duration, provide an initial estimate of the drug’s safety and efficacy. Moreover, they provide useful information in preparation for Phase III trials, or therapeutic confirmatory trials. This information includes an estimation of the most appropriate dosage(s), determination of the relevant endpoint(s), and other elements of study design, experimental methodology, and statistical analysis (Turner). Phase III therapeutic confirmatory trials typically involve around 3,000-5,000 participants with the medical condition of concern. (This number can be much smaller when studying a drug for a rare condition.) Phase III trials are typically longer in duration than Phase II trials. They are comparative in nature, so participants are randomized to a drug treatment group and a control treatment group. . In this column, we will consider the case of a superiority trial in which an investigational antihypertensive drug is tested against a placebo. (We will discuss equivalence trials and noninferiority trials in a future column.) The three primary goals in Phase III therapeutic confirmatory trials are: • Confirm the investigational drug’s efficacy and clinical usefulness. • Establish the drug’s clinical safety profile. • Assess the drug’s benefit:risk balance. The first two goals are addressed in this column, and the third will be addressed next month." @default.
- W137366449 created "2016-06-24" @default.
- W137366449 creator A5002654738 @default.
- W137366449 date "2009-01-01" @default.
- W137366449 modified "2023-09-26" @default.
- W137366449 title "Making Sense of Biostatistics: Therapeutic Confirmatory Trials" @default.
- W137366449 cites W2770598049 @default.
- W137366449 cites W2798722338 @default.
- W137366449 hasPublicationYear "2009" @default.
- W137366449 type Work @default.
- W137366449 sameAs 137366449 @default.
- W137366449 citedByCount "0" @default.
- W137366449 crossrefType "journal-article" @default.
- W137366449 hasAuthorship W137366449A5002654738 @default.
- W137366449 hasConcept C107130276 @default.
- W137366449 hasConcept C126322002 @default.
- W137366449 hasConcept C140556311 @default.
- W137366449 hasConcept C142724271 @default.
- W137366449 hasConcept C168563851 @default.
- W137366449 hasConcept C177713679 @default.
- W137366449 hasConcept C19527891 @default.
- W137366449 hasConcept C203092338 @default.
- W137366449 hasConcept C204787440 @default.
- W137366449 hasConcept C27081682 @default.
- W137366449 hasConcept C2780035454 @default.
- W137366449 hasConcept C2992672634 @default.
- W137366449 hasConcept C535046627 @default.
- W137366449 hasConcept C64903051 @default.
- W137366449 hasConcept C71924100 @default.
- W137366449 hasConcept C98274493 @default.
- W137366449 hasConceptScore W137366449C107130276 @default.
- W137366449 hasConceptScore W137366449C126322002 @default.
- W137366449 hasConceptScore W137366449C140556311 @default.
- W137366449 hasConceptScore W137366449C142724271 @default.
- W137366449 hasConceptScore W137366449C168563851 @default.
- W137366449 hasConceptScore W137366449C177713679 @default.
- W137366449 hasConceptScore W137366449C19527891 @default.
- W137366449 hasConceptScore W137366449C203092338 @default.
- W137366449 hasConceptScore W137366449C204787440 @default.
- W137366449 hasConceptScore W137366449C27081682 @default.
- W137366449 hasConceptScore W137366449C2780035454 @default.
- W137366449 hasConceptScore W137366449C2992672634 @default.
- W137366449 hasConceptScore W137366449C535046627 @default.
- W137366449 hasConceptScore W137366449C64903051 @default.
- W137366449 hasConceptScore W137366449C71924100 @default.
- W137366449 hasConceptScore W137366449C98274493 @default.
- W137366449 hasLocation W1373664491 @default.
- W137366449 hasOpenAccess W137366449 @default.
- W137366449 hasPrimaryLocation W1373664491 @default.
- W137366449 hasRelatedWork W13661692 @default.
- W137366449 hasRelatedWork W1497474955 @default.
- W137366449 hasRelatedWork W1964756699 @default.
- W137366449 hasRelatedWork W1969086475 @default.
- W137366449 hasRelatedWork W1982634085 @default.
- W137366449 hasRelatedWork W2014127930 @default.
- W137366449 hasRelatedWork W2031561768 @default.
- W137366449 hasRelatedWork W2037128447 @default.
- W137366449 hasRelatedWork W2087128386 @default.
- W137366449 hasRelatedWork W2098841909 @default.
- W137366449 hasRelatedWork W2109014571 @default.
- W137366449 hasRelatedWork W2147392006 @default.
- W137366449 hasRelatedWork W2154735846 @default.
- W137366449 hasRelatedWork W2161595156 @default.
- W137366449 hasRelatedWork W2295320555 @default.
- W137366449 hasRelatedWork W2387169812 @default.
- W137366449 hasRelatedWork W2403487417 @default.
- W137366449 hasRelatedWork W2414742965 @default.
- W137366449 hasRelatedWork W2513558015 @default.
- W137366449 hasRelatedWork W2032987475 @default.
- W137366449 isParatext "false" @default.
- W137366449 isRetracted "false" @default.
- W137366449 magId "137366449" @default.
- W137366449 workType "article" @default.